Brokerages expect that Catalent Inc (NYSE:CTLT) will announce $636.41 million in sales for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Catalent’s earnings. The lowest sales estimate is $623.80 million and the highest is $658.70 million. Catalent posted sales of $551.80 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 15.3%. The business is scheduled to report its next earnings results before the market opens on Tuesday, November 5th.
On average, analysts expect that Catalent will report full year sales of $2.85 billion for the current fiscal year, with estimates ranging from $2.82 billion to $2.88 billion. For the next financial year, analysts forecast that the firm will report sales of $3.07 billion, with estimates ranging from $3.04 billion to $3.09 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Catalent.
Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, August 27th. The company reported $0.65 EPS for the quarter, topping the consensus estimate of $0.62 by $0.03. Catalent had a return on equity of 15.89% and a net margin of 5.46%. The firm had revenue of $725.70 million for the quarter, compared to the consensus estimate of $719.20 million. During the same quarter last year, the company earned $0.67 earnings per share. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year.
In other Catalent news, Director Gregory T. Lucier purchased 2,000 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was purchased at an average cost of $51.64 per share, with a total value of $103,280.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO John R. Chiminski sold 97,043 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $48.84, for a total value of $4,739,580.12. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by insiders.
Hedge funds have recently modified their holdings of the stock. Nordea Investment Management AB lifted its stake in shares of Catalent by 1.3% during the 1st quarter. Nordea Investment Management AB now owns 109,340 shares of the company’s stock worth $4,438,000 after acquiring an additional 1,350 shares during the last quarter. Magnetar Financial LLC lifted its stake in shares of Catalent by 340.9% during the 2nd quarter. Magnetar Financial LLC now owns 104,480 shares of the company’s stock worth $5,664,000 after acquiring an additional 80,782 shares during the last quarter. Bailard Inc. bought a new stake in shares of Catalent during the 2nd quarter worth approximately $379,000. Virginia Retirement Systems ET AL lifted its stake in shares of Catalent by 19.3% during the 2nd quarter. Virginia Retirement Systems ET AL now owns 22,300 shares of the company’s stock worth $1,209,000 after acquiring an additional 3,600 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Catalent by 2.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,553,474 shares of the company’s stock worth $84,214,000 after acquiring an additional 32,691 shares during the last quarter.
Shares of NYSE CTLT traded up $0.89 during trading on Friday, hitting $49.30. The company had a trading volume of 513,100 shares, compared to its average volume of 807,718. The stock has a 50 day simple moving average of $49.72 and a 200 day simple moving average of $49.90. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.70 and a current ratio of 2.08. Catalent has a 12 month low of $29.23 and a 12 month high of $58.38. The firm has a market capitalization of $7.08 billion, a P/E ratio of 30.43, a price-to-earnings-growth ratio of 2.38 and a beta of 1.70.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: How is Preferred Stock Different from Common Stock?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.